These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 16900112)

  • 41. A novel approach to central venous catheter thrombosis in a patient with cystic fibrosis.
    Hull JH; Tucker W; Hatrick AG; Knight RK; Ho TB
    J Cyst Fibros; 2007 Nov; 6(6):417-8. PubMed ID: 17379581
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Problems with anti-clotting drug.
    Barinaga M
    Nature; 1988 Oct; 335(6193):751. PubMed ID: 3141814
    [No Abstract]   [Full Text] [Related]  

  • 43. Tissue plasminogen activator use in a patient with acute ischemic stroke coexisting with meningioma.
    Hsieh HC; Chen CH
    Clin Neurol Neurosurg; 2009 Jul; 111(6):562-3. PubMed ID: 19200644
    [No Abstract]   [Full Text] [Related]  

  • 44. Intravenous tissue plasminogen activator in central retinal artery occlusion.
    Falavarjani KG; Modarres M
    Am J Ophthalmol; 2009 Jun; 147(6):1105; author reply 1105-6. PubMed ID: 19463547
    [No Abstract]   [Full Text] [Related]  

  • 45. Review of tissue plasminogen activator, ischemic stroke, and potential legal issues.
    Liang BA; Lew R; Zivin JA
    Arch Neurol; 2008 Nov; 65(11):1429-33. PubMed ID: 19001160
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of extensive subacute portal, mesenteric and ileocolic vein thrombosis with recombinant tissue plasminogen activator.
    Hrstic I; Kalauz M; Cukovic-Cavka S; Ostojic R; Banfic L; Vucelic B
    Blood Coagul Fibrinolysis; 2007 Sep; 18(6):581-3. PubMed ID: 17762537
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effectiveness and cost effectiveness of thrombolysis in patients with acute pulmonary embolism.
    Zamanian RT; Gould MK
    Curr Opin Pulm Med; 2008 Sep; 14(5):422-6. PubMed ID: 18664972
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rapid EEG changes indicate reperfusion after tissue plasminogen activator injection in acute ischaemic stroke.
    Finnigan SP; Rose SE; Chalk JB
    Clin Neurophysiol; 2006 Oct; 117(10):2338-9. PubMed ID: 16926108
    [No Abstract]   [Full Text] [Related]  

  • 49. Medics dealing with use of t-Pa in strokes.
    Scott L
    Mod Healthc; 1996 Feb; 26(7):108. PubMed ID: 10172567
    [No Abstract]   [Full Text] [Related]  

  • 50. Why we can't trust clinical guidelines.
    Lenzer J
    BMJ; 2013 Jun; 346():f3830. PubMed ID: 23771225
    [No Abstract]   [Full Text] [Related]  

  • 51. [Treatment of acute ischemic apoplexy].
    Andersen G; Krieger DW; Iversen HK
    Ugeskr Laeger; 2009 Mar; 171(13):1094. PubMed ID: 19321089
    [No Abstract]   [Full Text] [Related]  

  • 52. Mortality of stroke patients treated with thrombolysis: analysis of nationwide inpatient sample.
    Flaherty ML; Kissela B; Khatri P
    Neurology; 2007 Feb; 68(9):710-1; author reply 711. PubMed ID: 17328117
    [No Abstract]   [Full Text] [Related]  

  • 53. Mortality of stroke patients treated with thrombolysis: analysis of nationwide inpatient sample.
    Kurth T; Heuschmann PU; Walker AM; Berger K
    Neurology; 2007 Feb; 68(9):710; author reply 711. PubMed ID: 17325289
    [No Abstract]   [Full Text] [Related]  

  • 54. Efficiency of alteplase in the treatment of venous and arterial thrombosis in neonates.
    Guérin V; Boisseau MR; Fayon M
    Am J Hematol; 1993 Feb; 42(2):236-7. PubMed ID: 8438893
    [No Abstract]   [Full Text] [Related]  

  • 55. Right brain: my first tPA.
    Robbins MS
    Neurology; 2009 Jul; 73(2):e9-e10. PubMed ID: 19597130
    [No Abstract]   [Full Text] [Related]  

  • 56. Current use of biologicals in thrombosis and haemostasis.
    Ofosu FA; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):805-6. PubMed ID: 18449409
    [No Abstract]   [Full Text] [Related]  

  • 57. Using tPA for acute stroke in a rural setting.
    Gross H; Hall C; Switzer JA; Adams RJ; Wang S; Hess DC; Nichols FT; Pardue C
    Neurology; 2007 May; 68(22):1957-8; author reply 1958. PubMed ID: 17536059
    [No Abstract]   [Full Text] [Related]  

  • 58. Genentech stops making TPA.
    Wagner M
    Mod Healthc; 1988 Oct; 18(43):5. PubMed ID: 10325205
    [No Abstract]   [Full Text] [Related]  

  • 59. Genentech's glyco-engineered antibody to succeed Rituxan.
    Ratner M
    Nat Biotechnol; 2014 Jan; 32(1):6-7. PubMed ID: 24406911
    [No Abstract]   [Full Text] [Related]  

  • 60. Genentech gets patent protection for tissue plasminogen activator.
    Ezzell C
    Nature; 1988 Jun; 333(6176):790. PubMed ID: 3133565
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.